KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Inovio Pharmaceuticals (INO) Assets Average (2016 - 2025)

Inovio Pharmaceuticals' Assets Average history spans 15 years, with the latest figure at $77.8 million for Q2 2025.

  • For Q2 2025, Assets Average changed N/A year-over-year to $77.8 million; the TTM value through Jun 2025 reached $77.8 million, changed N/A, while the annual FY2024 figure was $142.1 million, 45.3% down from the prior year.
  • Assets Average for Q2 2025 was $77.8 million at Inovio Pharmaceuticals, down from $100.2 million in the prior quarter.
  • Across five years, Assets Average topped out at $623.4 million in Q2 2021 and bottomed at $77.8 million in Q2 2025.
  • The 5-year median for Assets Average is $338.9 million (2022), against an average of $336.3 million.
  • The largest annual shift saw Assets Average soared 147.4% in 2021 before it plummeted 50.84% in 2023.
  • A 5-year view of Assets Average shows it stood at $515.9 million in 2021, then fell by 28.23% to $370.3 million in 2022, then tumbled by 50.84% to $182.0 million in 2023, then plummeted by 39.5% to $110.1 million in 2024, then dropped by 29.39% to $77.8 million in 2025.
  • Per Business Quant, the three most recent readings for INO's Assets Average are $77.8 million (Q2 2025), $100.2 million (Q1 2025), and $110.1 million (Q4 2024).